U.S. Markets closed

Cumberland Pharmaceuticals Inc. (CPIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.6600+0.0800 (+3.10%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.5800
Open2.8000
Bid2.6300 x 900
Ask2.6600 x 800
Day's Range2.6600 - 2.8500
52 Week Range2.6600 - 4.1800
Volume60,912
Avg. Volume69,556
Market Cap39.689M
Beta (5Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Cumberland Pharmaceuticals (CPIX) Beats Q4 Earnings and Revenue Estimates
    Zacks

    Cumberland Pharmaceuticals (CPIX) Beats Q4 Earnings and Revenue Estimates

    Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Recap: Cumberland Q4 Earnings

    Shares of Cumberland (NASDAQ:CPIX) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 88.89% over the past year to $0.01, which beat the estimate of ($0.01). Revenue of $10,262,000 declined by 24.97% year over year, which beat the estimate of $9,780,000. Outlook Cumberland hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. Conference Call Details Date: Mar 09, 2021 View more earnings on CPIX Time: 04:30 PM ET Webcast URL: https://edge.media-server.com/mmc/p/3x85aqjk Price Action 52-week high: $4.30 52-week low: $2.77 Price action over last quarter: Up 12.93% Company Profile Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It focuses on the acquisition, development, and commercialization of branded prescription products. The company provides prescription products to hospital acute care and gastroenterology to address unmet or poorly met medical needs. Its product brands include Acetadote, Caldolor, Kristalose, Omeclamox- Pak, Vaprisol and Ethyol. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 9, 2021Cumberland Earnings Preview© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Benzinga

    Cumberland Earnings Preview

    Cumberland (NASDAQ:CPIX) announces its next round of earnings this Tuesday, March 09. Here is Benzinga's look at Cumberland's Q4 earnings report. Net Income, Earnings, And Earnings Per Share Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding. Earnings And Revenue Wall Street analysts see Cumberland reporting a loss of $0.01 per share on revenue of $9.78 million. Cumberland EPS in the same period a year ago totaled $0.09. Revenue was $13.68 million. Why Analyst Estimates And Earnings Surprises Are Important Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin. View more earnings on CPIX If the company were to report earnings in line when it publishes results Tuesday, quarterly profit would be down 111.11%. Revenue would be down 28.5% from the same quarter last year. In comparison to analyst estimates in the past, here is how the company's reported EPS stacks up: Quarter Q3 2020 Q2 2020 Q1 2020 Q4 2020 EPS Estimate -0.07 0.03 0.02 0.01 EPS Actual 0.02 0.08 0.01 0.09 Revenue Estimate 8.61 M 9.27 M 9.46 M 11.34 M Revenue Actual 9.25 M 9.60 M 8.33 M 13.68 M Stock Performance Over the past 52-week period, shares of Cumberland have declined 26.28%. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Do not be surprised to see the stock move on comments made during its conference call. Cumberland is scheduled to hold the call at 16:30:00 ET and can be accessed here. See more from BenzingaClick here for options trades from BenzingaEarnings Preview for MongoDBAquestive Therapeutics Earnings Preview© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.